Hong Kong IT Stock News

Shougang Fushan Resources Group (SEHK:639) issued 2025 earnings guidance, flagging profit of HK$600 million to HK$700 million, compared with HK$1,494 million in 2024, as lower clean coking coal prices weigh on results. See our latest analysis for Shougang Fushan Resources Group. The earnings guidance lands after a strong run for investors, with the latest share price at HK$3.34 and a 1 year total shareholder return of 53.95% alongside a 5 year total shareholder return of 194.16%. This...

Bright Smart Securities & Commodities Group (SEHK:1428) is set to join the Hang Seng Composite Index, with the change effective March 9, 2026. This inclusion also paves the way for Shanghai Hong Kong Stock Connect eligibility. See our latest analysis for Bright Smart Securities & Commodities Group. The upcoming index inclusion sits on top of a strong run, with a 90 day share price return of 25% and a 1 year total shareholder return of 247.33% pointing to building momentum rather than fading...

Alcohol partnership with Songhe puts Guoquan Food’s beverage plans in focus Guoquan Food (Shanghai) (SEHK:2517) has signed an alcoholic beverage procurement agreement with Songhe Group, tying drinks more tightly to its hot pot and barbecue offerings across more than 11,000 retail stores. See our latest analysis for Guoquan Food (Shanghai). The new alcohol deal lands after a strong 1 year total shareholder return of 119.77%, even though recent momentum has softened. The 7 day share price...

FDA clearance puts CS2009 in focus for CStone investors CStone Pharmaceuticals (SEHK:2616) said the U.S. FDA has cleared its IND for a Phase II trial of immunotherapy candidate CS2009 in advanced solid tumors, expanding an ongoing global multicenter study. See our latest analysis for CStone Pharmaceuticals. The FDA clearance comes as CStone’s share price sits at HK$5.91, with a 7 day share price return of 14.98% and a 1 year total shareholder return of 113.36%. This suggests momentum has...

SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000 reported for 2024. See our latest analysis for SSY Group. At a share price of HK$3.02, SSY Group has a modest 1-day share price return of a 0.33% decline, while its year-to-date share price return of 5.59% contrasts with a 3-year total shareholder return of a 28.75% decline. This suggests that...

China Medical System Holdings (SEHK:867) has drawn fresh attention after Chinese regulators cleared human trials for its CMS-D017 kidney disease therapy, alongside a new AI-focused drug discovery partnership with Insilico Medicine. See our latest analysis for China Medical System Holdings. The recent CMS D017 trial clearance and AI drug discovery tie up come as China Medical System Holdings’ share price sits at HK$15.33, with a 30 day share price return of 9.34% and a 1 year total shareholder...

InnoCare Pharma (SEHK:9969) has drawn fresh attention after dosing the first patient in a Phase II/III trial of its TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across several other dermatology indications. See our latest analysis for InnoCare Pharma. Despite the steady stream of trial updates and the recent IND approval for ICP-538, InnoCare Pharma’s 90 day share price return decline of 14.51% contrasts with a 1 year total shareholder return of 91.23%,...

What recent performance data suggests about AIA Group (SEHK:1299) AIA Group (SEHK:1299) has drawn investor attention after a 1 day return of 2.55%, alongside a 1 year total return of 53.15% and a 3 year total return of 6.65%. See our latest analysis for AIA Group. That 2.55% 1 day share price return sits against a 7 day share price decline of 4.63% and a 90 day share price gain of 4.84%. The 1 year total shareholder return of 53.15% contrasts with a 5 year total shareholder return decline of...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hengan International Group fair value estimate is HK$34.85...

If you are wondering whether Tencent Holdings is attractively priced today or already reflects most of its potential, this article will walk you through how its current share price stacks up against several valuation checks. Tencent's share price last closed at HK$532.0, with a 2.8% decline over 7 days, a 13.8% decline over 30 days and a 14.6% decline year to date, while the 1 year return sits at 13.0% and the 3 year return at 45.8%, compared to a 19.6% decline over 5 years. Recent headlines...

As global markets navigate the complexities of AI disruption and economic shifts, Asian stocks have shown resilience, with indices like Japan's Nikkei 225 experiencing notable gains. In this environment, identifying undervalued stocks requires a keen eye for companies that demonstrate strong fundamentals and potential for growth amidst changing market conditions.

Lenovo Group recently reported third-quarter 2025/26 results showing record sales of US$22,204.33 million, alongside lower quarterly net income of US$545.54 million, while nine‑month profits edged higher year on year to US$1.39 billion. At the same time, Lenovo highlighted rapid growth in AI‑related revenue, restructured its Infrastructure Solutions Group for long-term AI opportunities, and launched new ThinkSmart–Huddly meeting solutions to deepen its presence in AI‑enabled...

The Meitu, Inc. ( HKG:1357 ) share price has fared very poorly over the last month, falling by a substantial 30...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

To the annoyance of some shareholders, TI Cloud Inc. ( HKG:2167 ) shares are down a considerable 28% in the last month...

With a price-to-earnings (or "P/E") ratio of 22.7x Kingsoft Corporation Limited ( HKG:3888 ) may be sending very...

Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...

Despite an already strong run, China Gingko Education Group Company Limited ( HKG:1851 ) shares have been powering on...

As global markets navigate concerns over AI disruption and fluctuating economic indicators, Asia's stock markets have shown resilience, with Japan experiencing significant gains following political developments and China maintaining steady growth despite deflationary pressures. In this climate of uncertainty, investors often look for companies with strong insider ownership as it can signal confidence in the company's prospects by those who know it best.

Why InSilico Medicine Cayman TopCo is on investors’ radar InSilico Medicine Cayman TopCo (SEHK:3696) has recently caught attention after a strong share price move, including an 18.3% return over the past week and 33.3% over the past month. See our latest analysis for InSilico Medicine Cayman TopCo. The recent jump in InSilico Medicine Cayman TopCo’s share price, with a 7 day share price return of 18.3% and 30 day share price return of 33.3%, sits within a much stronger year to date share...

What Cirrus Aircraft’s G3 Vision Jet Launch Means For Shareholders Cirrus Aircraft (SEHK:2507) has just begun delivering its Generation 3 Vision Jet, featuring an expanded seven seat layout, refreshed interior materials, and updated avionics including ATC Datalink and other flight deck refinements. This product launch gives investors a fresh reference point to consider Cirrus Aircraft’s position in personal aviation, in the context of its existing revenue of HK$1,316.235 million and net...

Why Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline. See our latest analysis for Suzhou Ribo Life Science. The latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a...

Akeso (SEHK:9926) has just received approval in China to start Phase II trials for AK139, a first in class IL-4Ra/ST2 bispecific antibody, targeting seven respiratory and autoimmune conditions. See our latest analysis for Akeso. Investors seem to be weighing Akeso's busy clinical calendar against recent volatility, with a 1 day share price return of 1.54% and 7 day return of 4.36% following the AK139 and ivonescimab updates. The 1 year total shareholder return of 74.92% points to strong...

Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate following its Breakthrough Therapy Designation in China. See our latest analysis for Alphamab Oncology. The JSKN003 milestone comes after a mixed run in the shares, with a 1-year total shareholder return of 124.81% contrasting with a 30-day share price return decline of 12.74% and longer term 3 and 5...